SBIR/STTR Research Award
SBIR Phase I: Antiviral and Anti-inflammatory Live Biotherapeutics (COVID-19)
Award amount
$256,000Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- General Probiotics Inc
- Proposal award date
- 2020-09-01
- Contract end date
- 2021-08-31
- UEI
- MM12NKQEXJN7
- Solicitation number
- Not reported
- Topic code
- PT
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of new therapeutics against coronavirus SARS-CoV-2 and associated COVID-19. Few broad-spectrum antivirals exist, and vaccines are
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Live therapeutics for prevention and control of necrotic enteritis associated with Clostridia perfringens in poultry
- Engineered probiotics to reduce Clostridia perfringes and prevent necrotic enteritis in chicken
- SBIR Phase II: New Antimicrobial Technologies to Eliminate Salmonella Carriage in Poultry
- SBIR Phase I: New antibiotic technologies to eliminate Salmonella carriage in poultry
Research funding history
5 SBIR/STTR records share this UEI (2016–2020). Reported award amounts total $1,789,225. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: National Science Foundation, Department of Agriculture